Cannabis prohibition has caused a lot of trouble over the years. From something as basic as social stigma to something as confounding as hyper-incarceration, the West has spent more than half a century looking down on cannabis in all its many forms.
Out of all the stifling that has happened under prohibition, the lack of high quality pre-clinical and clinical trials could be considered a root of the issue. Without studying it, how can we coherently evaluate our legal structure around it? With all the voices that have called out from mountain sides and living rooms trying to tell us there is much value in the plant, the scientific community has had a small group of voices ready to publicly contradict the general narrative. Luckily that is beginning to change, but we still need to continue to apply pressure for more formal, public research.
Case in point is CBDa. This non-psychotropic compound, in its natural state surrounded by other acidic cannabinoids and terpenes, has repeatedly demonstrated a safety profile that begs the question: what is holding us back from studying it more? Why aren’t there more studies? We wish we had a reasonable answer and solution to that.
One factor is funding. CBDa is a naturally occurring and abundant compound found in modern hemp varieties, and is therefore not “novel” (meaning it can’t be patented). Some of the best peer reviewed research we have on CBDa is using a synthetic methyl ester form CBDa. What is that, you ask? It is not directly from the plant, therefore it is a form of CBDa that can be patented and thus more appealing to privately funded research institutions.
In these methyl ester, peer reviewed research papers, in vitro experiments showed CBDa having an impressive affinity (≥ an order of magnitude more than THC or CBD) for the 5-HT2A serotonin receptor, a key site for all-to-common disorders such as anxiety, depression and even anticipatory nausea. In my own life, and in feedback from many of our customers, we have seen amazing shifts in symptoms from these common sources of discomfort when using CBDa in conjunction with treatments such as exercise, therapy and shifts in diet. I am not arguing CBDa is a cure for any symptoms, just noting the prevalence of correlation to lower adverse symptoms for some people when CBDa is part of their wellness program. My point continues to be we need more research!
Those 5-HT2A serotonin receptors are found all over the body, with high concentrations in the prefrontal cortex (decision making, emotions, sleep regulation, etc.) and…the GI tract. The fact we have this major component of our emotional chemistry in the gut is just one more point of interest for those learning about gut-brain interactions, right? We need more research!
Until that day comes, thanks to the 2018 Farm Bill, Circle Labs is able to offer you this naturally complex, clean and stable product, with a reliable concentrations of CBDa, for your interest and experience.
Always consult with your doctor before adding or subtracting anything from your wellness routine and remember, no one thing is the solution to all that ails you. CBDa is not right for everyone. If you are going to give it a try, start low (dose), go slow (try the same dose for at least 4-5 days before changing anything), talk to you doctor and listen to your body!
Wishing you all the best in health and wellness,
Adam and Ron